FindTrial
Sign In

Ampligen

DRUG8 trials

Sponsors

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Aim Immunotech Inc., National Institute of Allergy and Infectious Diseases (NIAID), HEM Research, AIM ImmunoTech Inc.

Conditions

Chronic Fatigue SyndromeFallopian Tube CancerHIV InfectionsMetastatic pancreatic cancerMyalgic EncephalomyelitisOvarian CancerPrimary Peritoneal Cancerlocally advanced pancreatic cancer

Phase 1

A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects
CompletedNCT00000713
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1992-10-31Target: 40Updated: 2021-11-03
A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC
CompletedNCT00000735
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1990-02-28Target: 12Updated: 2021-11-03
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
TerminatedNCT01312389
Abramson Cancer Center at Penn MedicineFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Start: 2011-04-30End: 2012-08-17Updated: 2021-11-15
Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy. DURIPANC Study
RecruitingCTIS2024-514597-42-00
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Metastatic pancreatic cancer
Start: 2024-01-16Target: 43Updated: 2025-05-28

Phase 2

A Phase 2, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Ampligen® Compared to Control Group / No Treatment Following FOLFIRINOX in Subjects with Locally Advanced Pancreatic Adenocarcinoma
Not yet recruitingCTIS2024-518627-29-00
Aim Immunotech Inc.locally advanced pancreatic cancer
Target: 30Updated: 2024-12-05

Phase 3

The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
CompletedNCT00215800
AIM ImmunoTech Inc.Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Start: 1998-12-31End: 2004-02-29Target: 234Updated: 2013-04-17

Unknown Phase

A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection
CompletedNCT00001000
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1990-01-31Target: 20Updated: 2012-10-19
A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen
CompletedNCT00002269
HEM ResearchHIV Infections
Updated: 2005-06-24

Related Papers

Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
PLoS ONE2020-10-2934 citations
A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.
2012-03-1454 citations